Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).

Authors

Guru P. Sonpavde

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Guru P. Sonpavde , Petros Grivas , Matthew I. Milowsky , Matt D. Galsky , Rajesh K. Malik , Andrew Paul Beelen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

First Author: Petros Grivas

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05.

First Author: F. Zappa

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).

First Author: Matt D. Galsky

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).

First Author: Inkeun Park